Barclays PLC Myovant Sciences Ltd. Transaction History

Barclays PLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $1.94 Million - $2.18 Million	80,746 Added 80.67%	180,840 $4.88 Million
Q3 2022 Nov 03, 2022	BUY	$11.6 - $20.44 $998,678 - $1.76 Million	86,093 Added 614.91%	100,094 $1.8 Million
Q2 2022 Aug 12, 2022	SELL	$7.78 - $14.69 $180,270 - $340,381	-23,171 Reduced 62.33%	14,001 $174,000
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $423,017 - $609,620	37,172 New	37,172 $495,000
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $73,653 - $122,858	-5,147 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$18.94 - $26.99 $71,858 - $102,400	3,794 Added 280.41%	5,147 $116,000
Q2 2021 Aug 13, 2021	SELL	$17.07 - $24.56 $293,313 - $422,014	-17,183 Reduced 92.7%	1,353 $31,000
Q1 2021 May 13, 2021	SELL	$20.46 - $25.18 $572,143 - $704,133	-27,964 Reduced 60.14%	18,536 $381,000
Q4 2020 Feb 11, 2021	SELL	$13.8 - $27.62 $340,860 - $682,214	-24,700 Reduced 34.69%	46,500 $1.28 Million
Q3 2020 Nov 12, 2020	SELL	$14.05 - $22.6 $115,210 - $185,320	-8,200 Reduced 10.33%	71,200 $1 Million
Q2 2020 Aug 12, 2020	BUY	$7.34 - $20.84 $582,796 - $1.65 Million	79,400 New	79,400 $1.64 Million
Q1 2020 May 13, 2020	SELL	$6.55 - $14.76 $172,265 - $388,188	-26,300 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$4.2 - $19.21 $62,928 - $287,823	14,983 Added 132.39%	26,300 $408,000
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $11,594 - $21,133	2,234 Added 24.6%	11,317 $59,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $78,931 - $227,075	9,083 New	9,083 $82,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.